jRCT2080223539已完成3 期
A Phase III,Multicenter, Randomized,Double-Blind,Placebo-Controlled,Parallel-Group,Efficacy And Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 750
- 试验地点
- 1
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Multicenter,randomized,double-blind,placebo-controlled,parallel-group
- 主要目的
- Treatment Purpose
入排标准
- 年龄范围
- 50age old over 至 85age old under（—）
- 性别
- All
入选标准
- •Meet NIA-AA core clinical criteria for probable AD dementia or prodromal AD
- •Having mild symptomatology, as defined by a screening MMSE score of 22 points and higher, and CDR-GS of 0.5 or 1.0
排除标准
- •Any evidence of a condition other than AD that may affect cognition
- •Meet the exclusion criteria of MRI at screening
结局指标
主要结局
-
safety efficacy Observation/Examination
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A study to learn how BAY2927088 is taken up and handled by the body in healthy male participantsCTIS2022-502771-38-00Bayer AG8
进行中（未招募）
1 期
A study in healthy men to test whether BI 1015550 influences the amount of nintedanib and pirfenidone in the bloodHealthy volunteer trialMedDRA version: 21.0Level: LLTClassification code: 10053349Term: Pharmacokinetic study Class: 10022891CTIS2023-505522-34-00Boehringer Ingelheim International GmbH14
招募中
1 期
A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Selnoflast in Participants with Moderate to Severe AsthmaModerate to Severe AsthmaMedDRA version: 20.0Level: PTClassification code: 10003553Term: Asthma Class: 100000004855CTIS2023-504304-29-00F. Hoffmann-La Roche AG90
进行中（未招募）
1 期
A study to learn about how much emodepside gets absorbed in the blood and how food affects its absorption when given as a new type of tablet to healthy participantsCTIS2023-508905-26-00Bayer AG40
进行中（未招募）
1 期
First-in-human study of 225Ac-PSMA-Trillium (BAY 3563254) in participants with advanced metastatic castration-resistant prostate cancer (mCRPC)Advanced metastatic castration-resistant prostate cancer with prostate specific membrane antigen (PSMA) expressionMedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104CTIS2023-507486-26-00Bayer Consumer Care AG135